H.C. Wainwright initiated coverage of Molecular Partners (MOLN) with a Buy rating and $13 price target The company is advancing a “diversified portfolio of agents” centered on the DARPin platform, the analyst tells investors in a research note. The firm says Molecular Partners is focused on targeted radiotherapy agents to address areas of serious unmet needs within oncology.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOLN:
- Molecular Partners Launches New Clinical Trials and Maps 2026 Milestones Ahead of J.P. Morgan Healthcare Conference
- Molecular Partners provided update on latest progress, 2026 milestones
- Molecular Partners forms Scientific Advisory Board
- Promising Pipeline and Strategic Focus Drive Buy Rating for Molecular Partners
- Molecular Partners price target lowered to CHF 3 from CHF 3.50 at JPMorgan